Skip to content
ContentLora

    Tip: press / anywhere to search.

    technology

    Lipid nanoparticle delivery for gene editing

    Also known as LNP, LNPs, lipid nanoparticles

    Lipid nanoparticles (LNPs) are tiny lipid carriers that can deliver gene-editor mRNA and guide RNA into the body, and they have carried the in vivo CRISPR and base-editing therapies described here to the liver.[1][2][3] Reaching organs other than the liver remains a challenge.[1]

    Editor reviewedStrict sourcingUpdated Gene editing and gene therapyLife sciencesHealth and medicine
    Key facts

    Lipid nanoparticles are a non-viral way to deliver gene editors into the body. They are an alternative to viral vectors such as AAV, which can carry only about 4.7 kilobases of DNA.[4] This page covers their use in gene editing.

    How LNPs deliver editors

    An LNP packages the editor as messenger RNA along with the guide RNA, and is given by infusion.[1][2] A 2024 review notes that planning LNP delivery to tissues other than the liver remains a challenge.[1] All the LNP programs listed below edit genes in the liver.[2][5][3] By contrast, the review notes that long-lasting Cas9 expression from AAV vectors may cause off-target effects.[4]

    Clinical track record

    • NTLA-2001 (2021). An LNP carrying Cas9 mRNA and a TTR-targeting guide lowered serum TTR by a mean 87% at 0.3 mg/kg, with mainly mild adverse events.[2]
    • CTX310 (2025). An LNP-delivered CRISPR therapy editing ANGPTL3 in liver cells. At the highest dose it lowered triglycerides by a mean 55% and LDL cholesterol by 49%, with no treatment-related serious adverse events reported.[5]
    • Personalized CPS1 base editor (2025). A base editor delivered by LNPs to the liver of one infant.[3] A year later the hospital reported continued good tolerance and better protein handling.[6]
    • Lonvo-z (2026). In a Phase 3 trial of 80 patients, a single 50 mg infusion cut hereditary angioedema attacks by 87% versus placebo, with no serious or Grade 3 or higher adverse events reported in the treated group.[7][8]
    • CTX310 at one year (2026). The highest dose kept ANGPTL3 a mean 79% below baseline, with triglycerides 48% and LDL cholesterol 53% lower.[9]

    Safety signals

    For in vivo CRISPR editing in general, liver safety has been the most visible concern. In October 2025 the FDA placed holds on Intellia’s nex-z Phase 3 trials after Grade 4 liver transaminase elevations and raised bilirubin in one patient.[10] That patient died in November 2025; the investigator reported septic shock from a perforated duodenal ulcer as the cause, with acute liver injury also part of the clinical course.[11] The holds were lifted in January and March 2026 with enhanced liver monitoring.[12] An analysis of more than 600 trial samples later linked the largest liver enzyme rises to one HLA gene variant, and Intellia said it would share genotyping results with investigators and enrolling patients.[13] The intellia-therapeutics page has details. In April 2026 the FDA proposed next-generation sequencing methods for assessing unintended edits in nonclinical studies.[14]

    How LNPs compare with other delivery routes

    RouteHow it worksTrade-offs
    Ex vivo electroporationCells are edited outside the body with electric pulses, then returnedAvoids in vivo delivery problems, but needs stem cell collection and conditioning
    AAV vectorA modified virus carries DNA encoding the editorCargo limited to about 4.7 kb; long-lasting expression may raise off-target risk
    Lentiviral vectorA modified virus integrates its cargo into the genomeLong expression; continuous Cas9 raises off-target chance
    Lipid nanoparticleLipid particle carries editor mRNA and guide RNAReaches the liver well; other tissues remain a challenge

    The table summarizes a 2024 review of CRISPR delivery and the Casgevy treatment process.[15][16][4][17][1] A 2025 review adds that in vivo approaches in general still face lower delivery efficiency and off-target effects than ex vivo editing.[18] The crispr-therapeutics and base-editing pages list the programs that rely on LNPs.

    Where LNP delivery is heading

    Two directions would take LNPs past single-gene liver targets. CRISPR Therapeutics says it is working on editing blood-forming stem cells inside the body with LNPs, which would avoid cell collection and conditioning.[19] It is also building an in vivo CAR-T platform that uses antibody-targeted LNPs to deliver editing to immune cells.[20] A hybrid route pairs an LNP carrying editor mRNA with an AAV supplying guide RNAs, reported in March 2026 for urea cycle disorders.[21] The same lipid-nanoparticle chemistry carries mRNA vaccines; see how lipid nanoparticles deliver RNA.

    Questions readers ask

    Why are lipid nanoparticles used for gene editing?

    They can carry editor mRNA and guide RNA into cells after an infusion, and they reach the liver well. Studies such as NTLA-2001 showed this can edit liver genes in people.[1][2]

    Can LNPs reach organs other than the liver?

    Reliably targeting tissues other than the liver remains a challenge, according to a 2024 review of CRISPR delivery.[1]

    What safety issues have in vivo editing trials raised?

    The 2021 NTLA-2001 study reported mainly mild adverse events, but in 2025 the FDA paused Intellia's nex-z Phase 3 trials after a patient had a severe liver reaction. The holds were lifted in early 2026 with added liver monitoring.[2][10][12]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      Lipid nanoparticles can carry Cas9 mRNA and guide RNA into tissues, but reliably targeting tissues other than the liver remains a challenge. confirmedas of 2026-10-10

    2. [2]

      In a 2021 NEJM study, NTLA-2001, a lipid nanoparticle carrying Cas9 mRNA and a guide RNA targeting the TTR gene, given by infusion, lowered blood TTR protein by a mean 87% at the 0.3 mg/kg dose, with mainly mild adverse events. confirmedas of 2026-10-10

    3. [3]

      In 2025 a team at Children's Hospital of Philadelphia and Penn Medicine designed and manufactured, within about six months, a personalized base-editing therapy delivered by lipid nanoparticles to the liver for an infant with severe CPS1 deficiency, a rare urea-cycle disorder. confirmedas of 2026-10-10

    4. [4]

      Adeno-associated virus (AAV) vectors carry a single-stranded DNA genome of about 4.7 kilobases, which limits cargo size, and their long-lasting expression of Cas9 may raise off-target risk. confirmedas of 2026-10-10

    5. [5]

      In November 2025 CRISPR Therapeutics reported Phase 1 data, published in NEJM, for CTX310, an LNP-delivered CRISPR therapy that edits the ANGPTL3 gene in liver cells; at the highest dose mean ANGPTL3 fell 73%, triglycerides 55% and LDL cholesterol 49%, with no treatment-related serious adverse events reported. confirmedas of 2026-10-10

    6. [6]

      Children's Hospital of Philadelphia said in February 2026, one year after the first infusion, that the infant treated with the personalized CPS1 base editor had tolerated three infusions given from February through April 2025 with no serious side effects, handled more dietary protein, needed less nitrogen-scavenging medication and showed better ammonia control during childhood illnesses, and that the treatment is not a cure. confirmedas of 2026-02-24

    7. [7]

      In the Phase 3 HAELO trial, a single infusion of lonvo-z reduced hereditary angioedema attacks by 87% versus placebo over weeks 5 to 28 (mean monthly attack rate 0.26 versus 2.10), and 62% of treated patients were attack-free and therapy-free versus 11% on placebo. confirmedas of 2026-10-10

    8. [8]

      The HAELO Phase 3 trial randomized 80 patients 2:1 to a single 50 mg infusion of lonvo-z or placebo; median follow-up was 7.5 months as of 10 February 2026, and no serious or Grade 3 or higher adverse events were reported in the lonvo-z group. confirmedas of 2026-06-13

    9. [9]

      At the European Society of Cardiology Congress on 28 August 2026, CRISPR Therapeutics reported one-year Phase 1a follow-up for CTX310, with mean reductions from baseline at the highest dose of 79% for ANGPTL3, 48% for triglycerides and 53% for LDL cholesterol, and said no additional treatment-related adverse events had occurred since the previous update; the data were published in NEJM the same day. confirmedas of 2026-08-28

    10. [10]

      On 29 October 2025 the FDA placed clinical holds on Intellia's Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z after a patient dosed in MAGNITUDE had Grade 4 liver transaminase elevations and increased bilirubin. confirmedas of 2026-10-10

    11. [11]

      Intellia's August 2026 quarterly report states that the MAGNITUDE participant who had Grade 4 liver transaminase elevations and increased bilirubin after a nex-z dose died on 5 November 2025, and that the principal investigator reported the cause as septic shock secondary to a perforated duodenal ulcer, with a clinical course that also included acute liver injury treated with corticosteroids and an autopsy report supporting the clinical diagnoses. confirmedas of 2026-08-06

    12. [12]

      The FDA lifted the clinical hold on Intellia's MAGNITUDE-2 trial in January 2026 and the hold on MAGNITUDE in March 2026, after the company agreed to study modifications including enhanced monitoring of liver laboratory tests; enrollment then advanced in both Phase 3 trials. confirmedas of 2026-08-06

    13. [13]

      In August 2026 Intellia said that a genomic analysis of more than 600 patient samples from nex-z trials, run with Regeneron and outside experts, found the highest observed liver transaminase elevations in patients carrying one specific HLA allele, and that it would give HLA genotyping results to investigators and to patients enrolled or entering screening in the ongoing Phase 3 trials. confirmedas of 2026-08-06

    14. [14]

      On 15 April 2026 the FDA published draft guidance recommending next-generation sequencing methods for the nonclinical safety assessment of genome editing in human gene therapy products, with comments due by 14 July 2026. confirmedas of 2026-10-10

    15. [15]

      For editing human stem cells outside the body, electroporation (using electric pulses to open cell membranes) is still the main choice, because it avoids the challenges of delivery inside the body. confirmedas of 2026-10-10

    16. [16]

      Treatment with Casgevy involves collecting the patient's own stem cells, editing them, giving myeloablative conditioning (high-dose chemotherapy) to clear the bone marrow, and infusing the edited cells back as a one-time treatment. confirmedas of 2026-10-10

    17. [17]

      Lentiviral vectors usually integrate their genome into the host's DNA, prolonging expression; continuous Cas9 expression increases the chance of off-target edits. confirmedas of 2026-10-10

    18. [18]

      Early CRISPR therapies edited cells outside the body (ex vivo); newer approaches deliver the editor into the patient (in vivo), which a 2025 review notes faces lower delivery efficiency, off-target effects and instability. confirmedas of 2026-10-10

    19. [19]

      CRISPR Therapeutics says it is advancing in vivo editing of blood-forming stem cells using lipid nanoparticle delivery, an approach it says could expand the treatable population for sickle cell disease and beta-thalassemia beyond ex vivo therapy. confirmedas of 2026-08-03

    20. [20]

      CRISPR Therapeutics is also developing gene-edited cell therapies beyond blood disorders: zugocabtagene geleucel (zugo-cel, formerly CTX112) is in Phase 1 trials in autoimmune disease and B-cell malignancies, and the company is building an in vivo CAR-T platform using an antibody-conjugated lipid nanoparticle system to deliver editing to immune cells. confirmedas of 2026-08-03

    21. [21]

      In March 2026 researchers at Children's Hospital of Philadelphia, Penn Medicine and the Broad Institute reported in The American Journal of Human Genetics a customizable two-part in vivo prime-editing platform for urea cycle disorders - a lipid nanoparticle carrying editor mRNA to the liver plus an AAV supplying guide RNAs - that corrected about 30 to 40% of copies of a disease-causing variant in preclinical liver DNA, above the roughly 10% the researchers consider necessary for clinical benefit. confirmedas of 2026-03-30

    Revision history (2)
    1. Page created.
    2. Added lonvo-z and CTX310 one-year results, the one-year personalized therapy update, the nex-z HLA finding, FDA guidance and future LNP directions.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Lipid nanoparticle delivery for gene editing." ContentLora, updated Oct 10, 2026. https://contentlora.com/wiki/lipid-nanoparticle-delivery

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    Connections
    CRISPR-Cas9 DeliversBase editing DeliversCRISPR Therapeutics Used byPersonalized (bespo… Used in
    ☰ Contents